Takayuki Kishikawa
5PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jul 20, 2023
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda
|Sep 05, 2022
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.Ken Masubuchi, Hisao Imai, Satoshi Wasamoto
|Aug 20, 2021
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.Hisao Imai, Takayuki Kishikawa, Hiroyuki Minemura
|Aug 27, 2020
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.Hisao Imai, Hiroyuki Minemura, Takayuki Kishikawa
|Mar 05, 2020
Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.Takayuki Kishikawa, Takashi Kasai, Masahiko Okada
Pageof 1
